{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T09:12:24Z","timestamp":1721293944975},"reference-count":53,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2016.00258","type":"journal-article","created":{"date-parts":[[2016,12,15]],"date-time":"2016-12-15T09:56:57Z","timestamp":1481795817000},"update-policy":"http:\/\/dx.doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Murine Models of Splenic Marginal Zone Lymphoma: A Role for Cav1?"],"prefix":"10.3389","volume":"6","author":[{"given":"Chelsey L.","family":"Patten","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine E.","family":"Cutucache","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2016,12,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/sj.leu.2405068","article-title":"Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria","volume":"22","author":"Matutes","year":"2008","journal-title":"Leukemia"},{"issue":"7","key":"B2","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.3109\/10428194.2012.743655","article-title":"Splenic marginal zone lymphoma: a population-based study on the 2001\u20132008 incidence and survival in the United States","volume":"54","author":"Liu","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12253-014-9845-z","article-title":"Non-Hodgkin lymphoma and hepatitis C: where we are and what next?","volume":"21","author":"Sulyok","year":"2014","journal-title":"Pathol Oncol Res"},{"issue":"2","key":"B4","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3109\/10428194.2014.919636","article-title":"Splenic marginal-zone lymphoma: ontogeny and genetics","volume":"56","author":"Baliakas","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1182\/blood-2002-07-2216","article-title":"Splenic marginal zone lymphoma","volume":"101","author":"Franco","year":"2003","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/978-3-319-13150-4_9","article-title":"Management of the marginal zone lymphomas","volume":"165","author":"Vannata","year":"2015","journal-title":"Cancer Treat Res"},{"key":"B7","author":"[SEER] Surveillance, Epidemiology, and End Results Program","year":"2016","journal-title":"National Institutes of Health"},{"issue":"2","key":"B8","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/leu.2014.294","article-title":"The Kr\u00fcppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma","volume":"29","author":"Piva","year":"2014","journal-title":"Leukemia"},{"issue":"18","key":"B9","doi-asserted-by":"publisher","first-page":"4174","DOI":"10.1158\/1078-0432.CCR-14-2759","article-title":"Genetics and prognostication in splenic marginal zone lymphoma: revelations from deep sequencing","volume":"21","author":"Parry","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"8","key":"B10","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1158\/1078-0432.CCR-15-1170","article-title":"An immunogenetic signature of ongoing antigen interactions in splenic marginal zone lymphoma expressing IGHV1-2*04 receptors","volume":"22","author":"Bikos","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"7","key":"B11","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/modpathol.2012.220","article-title":"Splenic marginal zone lymphoma: comprehensive analysis of gene expression and miRNA profiling","volume":"26","author":"Arribas","year":"2013","journal-title":"Mod Pathol"},{"key":"B12","volume-title":"Flow Cytometry, Immunohistochemistry, and Molecular Genetics for Hematologic Neoplams","author":"Tsieh","year":"2012"},{"key":"B13","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1186\/s12885-015-1766-z","article-title":"Whole exome sequencing of microdissected splenic marginal zone lymphoma: a study to discover novel tumor-specific mutations","volume":"15","author":"Peveling-Oberhag","year":"2015","journal-title":"BMC Cancer"},{"issue":"17","key":"B14","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1182\/blood-2015-11-624312","article-title":"Splenic marginal zone lymphoma: from genetics to management","volume":"127","author":"Arcaini","year":"2016","journal-title":"Blood"},{"issue":"12","key":"B15","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1182\/blood-2014-08-596247","article-title":"DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features","volume":"125","author":"Arribas","year":"2015","journal-title":"Blood"},{"issue":"5","key":"B16","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1182\/blood-2004-10-3898","article-title":"Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis","volume":"106","author":"Ruiz-Ballesteros","year":"2005","journal-title":"Blood"},{"issue":"9","key":"B17","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1084\/jem.20120904","article-title":"The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development","volume":"209","author":"Rossi","year":"2012","journal-title":"J Exp Med"},{"issue":"9","key":"B18","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1084\/jem.20120910","article-title":"Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma","volume":"209","author":"Kiel","year":"2012","journal-title":"J Exp Med"},{"issue":"20","key":"B19","doi-asserted-by":"publisher","first-page":"4918","DOI":"10.1182\/blood-2008-08-174110","article-title":"The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas","volume":"113","author":"Novak","year":"2009","journal-title":"Blood"},{"issue":"12","key":"B20","doi-asserted-by":"publisher","first-page":"e83244","DOI":"10.1371\/journal.pone.008324","article-title":"Whole exome sequencing identifies novel recurrently mutated genes in patients with splenic marginal zone lymphoma","volume":"8","author":"Parry","year":"2013","journal-title":"PLoS One"},{"issue":"9","key":"B21","doi-asserted-by":"publisher","first-page":"e44997","DOI":"10.1371\/journal.pone.0044997","article-title":"An integrated genomic and expression analysis of 7q deletion in splenic marginal zone lymphoma","volume":"7","author":"Watkins","year":"2012","journal-title":"PLoS One"},{"issue":"6","key":"B22","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1111\/j.1365-2141.2012.09226.x","article-title":"High-throughput sequencing analysis of the chromosome 7q32 deletion reveals IRF5 as a potential tumour suppressor in splenic marginal-zone lymphoma","volume":"158","author":"Fresquet","year":"2012","journal-title":"Br J Haematol"},{"issue":"12","key":"B23","doi-asserted-by":"publisher","first-page":"4643","DOI":"10.1182\/blood-2005-11-4659","article-title":"Splenic marginal zone lymphoma: a prognostic model for clinical use","volume":"107","author":"Arcaini","year":"2006","journal-title":"Blood"},{"issue":"5","key":"B24","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1182\/blood-2010-01-264275","article-title":"Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome","volume":"117","author":"Rinaldi","year":"2010","journal-title":"Blood"},{"issue":"5","key":"B25","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1038\/leu.2014.330","article-title":"KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype","volume":"29","author":"Clipson","year":"2015","journal-title":"Leukemia"},{"issue":"9","key":"B26","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1182\/blood-2010-02-267476","article-title":"Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-cell Lymphoma Group","volume":"116","author":"Salido","year":"2010","journal-title":"Blood"},{"issue":"6","key":"B27","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1182\/blood.V83.6.1558.1558","article-title":"The immunophenotype of splenic lymphoma with villous lymphocytes and its relevance to the differential diagnosis with other B-cell disorders","volume":"83","author":"Matutes","year":"1994","journal-title":"Blood"},{"issue":"8","key":"B28","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","article-title":"New approach to classifying non-Hodgkin\u2019s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin\u2019s lymphoma classification project","volume":"16","author":"Armitage","year":"1998","journal-title":"J Clin Oncol"},{"issue":"7","key":"B29","first-page":"601","article-title":"Absence of cyclin D1 protein expression in splenic marginal zone lymphoma","volume":"11","author":"Savilo","year":"1998","journal-title":"Mod Pathol"},{"issue":"4","key":"B30","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1182\/blood-2002-06-1801","article-title":"The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression","volume":"101","author":"Ghia","year":"2003","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"6955","DOI":"10.1073\/pnas.102181599","article-title":"Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression","volume":"99","author":"Bichi","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B32","doi-asserted-by":"publisher","first-page":"4441","DOI":"10.1182\/blood-2009-07-233718","article-title":"Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance","volume":"114","author":"Kurtova","year":"2009","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e2071","DOI":"10.1038\/cddis.2015.419","article-title":"TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemia","volume":"7","author":"Bresin","year":"2016","journal-title":"Cell Death Dis"},{"issue":"37","key":"B34","doi-asserted-by":"publisher","first-page":"26430","DOI":"10.1074\/jbc.M113.475913","article-title":"Accelerated development of chronic lymphocytic leukemia in New Zealand Black mice expressing a low level of interferon regulatory factor 4","volume":"288","author":"Ma","year":"2013","journal-title":"J Biol Chem"},{"issue":"16","key":"B35","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1182\/blood-2013-03-492769","article-title":"A role for IRF4 in the development of CLL","volume":"122","author":"Shukla","year":"2013","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.leukres.2015.10.008","article-title":"Isolation of a novel chronic lymphocytic leukemic (CLL) cell lines and development of an in vivo mouse model of CLL","volume":"40","author":"Kellner","year":"2016","journal-title":"Leuk Res"},{"issue":"11","key":"B37","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1242\/dmm.021147","article-title":"T-cell number and subtype influence the disease course of primary chronic lymphocytic leukaemia xenografts in alymphoid mice","volume":"8","author":"Oldreive","year":"2015","journal-title":"Dis Model Mech"},{"issue":"11","key":"B38","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.3109\/10428194.2015.1034701","article-title":"NOD\/SCID IL2R\u03b3-null mouse xenograft model of human p53-mutated chronic lymphocytic leukemia and ATM-mutated mantle cell lymphoma using permanent cell lines","volume":"56","author":"Verner","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"B39","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1053\/j.seminhematol.2014.05.001","article-title":"Murine genetically engineered and human xenograft models of chronic lymphocytic leukemia","volume":"51","author":"Chen","year":"2014","journal-title":"Semin Hematol"},{"issue":"11","key":"B40","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.3109\/10428194.2012.691481","article-title":"Establishment and characterization of therapy-resistant mantle cell lymphoma cell lines derived from different tissue sites","volume":"53","author":"Ahrens","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"B41","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1002\/ijc.27602","article-title":"Novel therapy for therapy-resistant mantle cell lymphoma: multipronged approach with targeting of hedgehog signaling","volume":"131","author":"Hegde","year":"2012","journal-title":"Int J Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/labinvest.2014.61","article-title":"Mouse models of mantle cell lymphoma, complex changes in gene expression and phenotype of engrafted MCL cells: implications for preclinical research","volume":"94","author":"Klanova","year":"2014","journal-title":"Lab Invest"},{"key":"B43","first-page":"1459","article-title":"Progression of spontaneous lymphomas in SJL mice: monitoring in vivo clonal evolution with molecular markers in sequential splenic samples","volume":"78","author":"Tang","year":"1998","journal-title":"Lab Invest"},{"key":"B44","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/S0002-9440(10)65327-8","article-title":"Splenic marginal zone lymphomas of mice","volume":"154","author":"Fredrickson","year":"1999","journal-title":"Am J Pathol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"13853","DOI":"10.1073\/pnas.95.23.13853","article-title":"A model for spontaneous B-lineage lymphomas in IgHmu-HOX11 transgenic mice","volume":"95","author":"Hough","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B46","first-page":"3","article-title":"Splenic marginal zone B-cell and thymic T-cell lymphomas in p53-deficient mice","volume":"50","author":"Ward","year":"1999","journal-title":"Lab Invest"},{"issue":"6","key":"B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2011\/984505","article-title":"Common fragile site tumor suppressor genes and corresponding mouse models of cancer","volume":"4","author":"Drusco","year":"2011","journal-title":"J Biomed Biotechnol"},{"issue":"2","key":"B48","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/j.1365-2141.2012.09148.x","article-title":"Lymph node-induced immune tolerance in chronic lymphocytic leukaemia: a role for caveolin-1","volume":"158","author":"Gilling","year":"2012","journal-title":"Br J Haematol"},{"issue":"6","key":"B49","first-page":"4581","article-title":"Caveloin-1 haploinsufficiency leads to partial transformation of human breast epithelial cells","volume":"23","author":"Zou","year":"2003","journal-title":"Anticancer Res"},{"issue":"4","key":"B50","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S0002-9440(10)64412-4","article-title":"Caveolin-1 mutations (P132L and null) behaves in a dominant-negative manner and caveolin01 (-\/-) null mice show mammary epithelial cell hyperplasia","volume":"161","author":"Lee","year":"2002","journal-title":"Am J Pathol"},{"issue":"1","key":"B51","doi-asserted-by":"publisher","first-page":"30.e","DOI":"10.1016\/j.exphem.2015.09.005","article-title":"Absence of caveolin-1 leads to delayed development of chronic lymphocytic leukemia in E\u00b5-TCL1 mouse model","volume":"44","author":"Shukla","year":"2016","journal-title":"Exp Hematol"},{"issue":"6","key":"B52","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.4049\/jimmunol.1101447","article-title":"Caveolin-1 orchestrates TCR synaptic polarity, signal specificity, and function in CD8 T cells","volume":"187","author":"Tomassian","year":"2011","journal-title":"J Immunol"},{"issue":"11","key":"B53","doi-asserted-by":"publisher","first-page":"e0142682","DOI":"10.1371\/journal.pone.0142682","article-title":"Conserved molecular underpinnings and characterization of a role for caveolin-1 in the tumor microenvironment of mature T-cell lymphomas","volume":"10","author":"Herek","year":"2015","journal-title":"PLoS One"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fonc.2016.00258\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T23:57:08Z","timestamp":1601251028000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fonc.2016.00258\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,14]]},"references-count":53,"URL":"https:\/\/doi.org\/10.3389\/fonc.2016.00258","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,14]]}}}